Research Publications:@0.674285:0.063855:0.896201:0.063855:0.896201:0.040840:0.674285:0.040840:0.016980:0.010442:0.009149:0.010442:0.011759:0.010014:0.010442:0.013076:0.005456:0.014370:0.013076:0.013076:0.006538:0.006538:0.010442:0.011759:0.007832:0.006538:0.011759:0.013076:0.009149
Inhibition Of Colorectal Cancer Targets Il-6, Ctla-4, & B7-2 By :@0.104762:0.111208:0.882698:0.111208:0.882698:0.083261:0.104762:0.083261:0.011109:0.015878:0.015878:0.007939:0.015878:0.007939:0.009510:0.007939:0.014279:0.015878:0.007140:0.022218:0.009510:0.007140:0.020619:0.014279:0.007939:0.014279:0.012163:0.012680:0.012680:0.009510:0.014279:0.007939:0.007140:0.020619:0.014279:0.015878:0.012680:0.012680:0.012146:0.006625:0.016427:0.014279:0.012680:0.014279:0.012680:0.009510:0.011109:0.007140:0.011109:0.007939:0.009510:0.014279:0.007140:0.007140:0.020619:0.009510:0.007939:0.014279:0.009510:0.014279:0.007140:0.007140:0.023789:0.007140:0.019048:0.014279:0.009510:0.014279:0.007140:0.019048:0.014279:0.007140
Tislelizumab: Molecular Docking, Dynamics, & String Protein-:@0.104762:0.137337:0.874219:0.137337:0.874219:0.109391:0.104762:0.109391:0.018531:0.007939:0.011109:0.007939:0.012680:0.007939:0.007939:0.012680:0.015878:0.023789:0.014279:0.015878:0.009510:0.007140:0.026959:0.014279:0.007939:0.012680:0.012680:0.015878:0.007939:0.014279:0.012129:0.007140:0.020619:0.014279:0.012680:0.015878:0.007939:0.015878:0.014279:0.007140:0.007140:0.020619:0.014279:0.015878:0.014279:0.023789:0.007939:0.012680:0.011109:0.007140:0.007140:0.023789:0.007140:0.015878:0.009510:0.012680:0.007939:0.015878:0.014279:0.007140:0.017449:0.012163:0.014279:0.009510:0.012680:0.007939:0.015878:0.009510
Protein Network Analysis:@0.104762:0.163466:0.416774:0.163466:0.416774:0.135520:0.104762:0.135520:0.017449:0.012154:0.014279:0.009510:0.012680:0.007939:0.015878:0.007137:0.020619:0.012680:0.009510:0.020619:0.014279:0.012680:0.015878:0.005569:0.020619:0.015878:0.014279:0.007939:0.014279:0.011109:0.007939:0.011109
Informatics In Medicine Unlocked. 2023; 41: 101323. :@0.239166:0.188085:0.767673:0.188085:0.767673:0.165818:0.239166:0.165818:0.009149:0.013076:0.007832:0.011759:0.009149:0.018297:0.011759:0.006538:0.006538:0.010442:0.009149:0.005880:0.009149:0.013076:0.005880:0.020908:0.010442:0.011759:0.006538:0.010442:0.006538:0.013076:0.010442:0.005880:0.016980:0.013076:0.006538:0.011759:0.010442:0.011759:0.010442:0.011759:0.005880:0.005880:0.011759:0.011759:0.011759:0.011759:0.007832:0.005880:0.011759:0.011759:0.007832:0.005880:0.011759:0.011759:0.011759:0.011759:0.011759:0.011759:0.005880:0.005880
------------------------------------------------------------------------------------:@0.171550:0.214209:0.829409:0.214209:0.829409:0.191810:0.171550:0.191810:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832:0.007832
Mahmoud Elkazzaz, Shahid Ullah, Tianshun Gao, Israa M. Shamkh, Amr Ahmed,:@0.128489:0.239984:0.872467:0.239984:0.872467:0.219308:0.128489:0.219308:0.019415:0.010919:0.012142:0.016990:0.010919:0.012142:0.010919:0.005460:0.014566:0.006071:0.010919:0.010919:0.008495:0.008495:0.010919:0.008495:0.005460:0.005460:0.012142:0.012142:0.010919:0.012142:0.006071:0.010919:0.005460:0.015767:0.006071:0.006071:0.010919:0.012142:0.005460:0.005460:0.012548:0.006071:0.010919:0.012142:0.008495:0.012142:0.012142:0.012142:0.005460:0.015767:0.010919:0.010919:0.005460:0.005460:0.008495:0.008495:0.008495:0.010919:0.010919:0.005460:0.019415:0.005460:0.005460:0.012142:0.012142:0.010919:0.016990:0.010919:0.012142:0.005460:0.004687:0.014566:0.016990:0.008495:0.004649:0.014566:0.012142:0.016990:0.009696:0.010919:0.005460
Ted X. Wu G, Maii S. Elsharayidi, Mohammad Shahbaz Khan, Aziz-Ur Rehman,:@0.137705:0.266111:0.863243:0.266111:0.863243:0.245434:0.137705:0.245434:0.011334:0.009696:0.010919:0.005460:0.014566:0.005460:0.005062:0.018213:0.012142:0.005460:0.015767:0.005460:0.005460:0.019415:0.010919:0.006071:0.006071:0.005460:0.012142:0.005460:0.005460:0.014566:0.006071:0.008495:0.012142:0.010919:0.008495:0.010919:0.009696:0.006071:0.010919:0.006071:0.005460:0.005460:0.019415:0.010919:0.012142:0.010919:0.016990:0.016990:0.010919:0.010919:0.005460:0.012142:0.012142:0.010919:0.012142:0.010919:0.010919:0.008495:0.005460:0.014566:0.012142:0.010919:0.012142:0.005460:0.004671:0.014566:0.008495:0.006071:0.008495:0.007272:0.015767:0.008495:0.005460:0.014566:0.009696:0.012142:0.016990:0.010919:0.012142:0.005460
Marwa M. Lotfy, Abdullah Haikal, Mahmoud Abdalrahman:@0.229558:0.292237:0.771383:0.292237:0.771383:0.271561:0.229558:0.271561:0.019415:0.010919:0.008495:0.014566:0.010919:0.005460:0.019415:0.005460:0.005460:0.013343:0.010919:0.006071:0.007272:0.008886:0.005460:0.004649:0.014566:0.010919:0.010919:0.012142:0.006071:0.006071:0.010919:0.012142:0.005460:0.016990:0.010919:0.006071:0.010919:0.010919:0.006071:0.005460:0.005460:0.019415:0.010919:0.012142:0.016990:0.010919:0.012142:0.010919:0.004643:0.014566:0.010919:0.010919:0.010919:0.006071:0.008495:0.010919:0.012142:0.016990:0.010919:0.012142
Abstract:@0.104762:0.330063:0.213026:0.330063:0.213026:0.302116:0.104762:0.302116:0.020905:0.016164:0.011395:0.009795:0.012965:0.014565:0.012965:0.009510
As a DNA mismatch repair deficit (dMMR) anticancer medication, and a humanized monoclonal :@0.104762:0.351654:0.900382:0.351654:0.900382:0.332454:0.104762:0.332454:0.014756:0.008043:0.004374:0.009152:0.004374:0.014756:0.014756:0.013645:0.004374:0.015885:0.005806:0.008043:0.015885:0.009152:0.005806:0.009152:0.010281:0.004374:0.006914:0.009152:0.010281:0.009152:0.005806:0.006914:0.004374:0.010281:0.009152:0.006914:0.005806:0.009152:0.005806:0.005806:0.004374:0.006914:0.010281:0.018123:0.018123:0.013647:0.006914:0.004374:0.009152:0.010281:0.005806:0.005806:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.004374:0.015885:0.009152:0.010281:0.005806:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.005241:0.004374:0.009152:0.010281:0.010281:0.004374:0.009152:0.004374:0.010281:0.010281:0.015885:0.009152:0.010281:0.005806:0.009152:0.009152:0.010281:0.004374:0.015885:0.010281:0.010281:0.010281:0.009152:0.005806:0.010281:0.010281:0.009152:0.005602:0.005040
antibody (hmAb), Tislelizumab has attracted significant interest in recent years. The programmed :@0.104762:0.368758:0.900380:0.368758:0.900380:0.349559:0.104762:0.349559:0.009152:0.010281:0.005806:0.005806:0.010281:0.010281:0.010281:0.010281:0.003891:0.006914:0.010281:0.015885:0.014756:0.010281:0.006914:0.005241:0.003530:0.011805:0.005806:0.008043:0.005806:0.009152:0.005806:0.005806:0.009152:0.010281:0.015885:0.009152:0.010281:0.003891:0.010281:0.009152:0.008043:0.003891:0.009152:0.005806:0.005806:0.006914:0.009152:0.009152:0.005806:0.009152:0.010281:0.003891:0.008043:0.005806:0.010281:0.010281:0.005806:0.006914:0.005806:0.009152:0.009152:0.010281:0.005806:0.003891:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.008043:0.005806:0.003891:0.005806:0.010281:0.003891:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.003891:0.010281:0.009152:0.009152:0.006914:0.008043:0.005241:0.003528:0.012519:0.010281:0.009152:0.003891:0.010281:0.006914:0.010281:0.010281:0.006914:0.009152:0.015885:0.015885:0.009152:0.010079:0.005040
cell death protein-1 (PD-1) and its ligands (PD-L1/CD274/B7-H1 and PDL2/CD273) may :@0.104762:0.385863:0.900386:0.385863:0.900386:0.366663:0.104762:0.366663:0.009152:0.009152:0.005806:0.005806:0.009878:0.010281:0.009152:0.009152:0.005806:0.010281:0.009878:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.006914:0.010281:0.009878:0.006914:0.011410:0.014756:0.006914:0.010281:0.006914:0.009878:0.009152:0.010281:0.010281:0.009878:0.005806:0.005806:0.008043:0.009878:0.005806:0.005806:0.010281:0.009152:0.010281:0.010281:0.008043:0.009878:0.006914:0.011410:0.014756:0.006914:0.012519:0.010281:0.005806:0.013647:0.014756:0.010281:0.010281:0.010281:0.005806:0.013647:0.010281:0.006914:0.014756:0.010281:0.009878:0.009152:0.010281:0.010281:0.009878:0.011410:0.014756:0.012519:0.010281:0.005806:0.013647:0.014756:0.010281:0.010281:0.010281:0.006914:0.009878:0.015885:0.009152:0.010079:0.005040
bind to each other with great affinity. This binding prevents activated T-cells from continuing :@0.104762:0.402967:0.900388:0.402967:0.900388:0.383767:0.104762:0.383767:0.010281:0.005806:0.010281:0.010281:0.006781:0.005806:0.010281:0.006783:0.009152:0.009152:0.009152:0.010281:0.006783:0.010281:0.005806:0.010281:0.009152:0.006914:0.006781:0.014756:0.005806:0.005806:0.010281:0.006783:0.010281:0.006914:0.009152:0.009152:0.005806:0.006781:0.009152:0.006552:0.006914:0.005806:0.010281:0.005806:0.005806:0.008971:0.005241:0.006421:0.012519:0.010281:0.005806:0.008043:0.006783:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.006783:0.010281:0.006914:0.009152:0.010281:0.009152:0.010281:0.005806:0.008043:0.006781:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.005806:0.009152:0.010281:0.006419:0.010666:0.006914:0.009152:0.009152:0.005806:0.005806:0.008043:0.006783:0.006914:0.006914:0.010281:0.015885:0.006783:0.009152:0.010281:0.010281:0.005806:0.005806:0.010281:0.010281:0.005806:0.010281:0.010079:0.005040
to proliferate, produce cytokines, and engage in cytotoxic action.  The B7:PD-1 inhibitory :@0.104762:0.420072:0.900420:0.420072:0.900420:0.400872:0.104762:0.400872:0.005806:0.010281:0.009979:0.010281:0.006914:0.010281:0.005806:0.005806:0.006914:0.009152:0.006914:0.009152:0.005806:0.009152:0.005241:0.009979:0.010281:0.006914:0.010281:0.010281:0.010281:0.009152:0.009152:0.009979:0.009152:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.009152:0.008043:0.005241:0.009979:0.009152:0.010281:0.010281:0.009979:0.009152:0.010281:0.010281:0.009152:0.010281:0.009152:0.009979:0.005806:0.010281:0.009979:0.009152:0.010281:0.005806:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.009979:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.005241:0.005040:0.004570:0.012519:0.010281:0.009152:0.009979:0.013647:0.010281:0.005806:0.011410:0.014756:0.006914:0.010281:0.009979:0.005806:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.010281:0.006914:0.010079:0.005040
immunological checkpoint receptor binds to the B7-2(CD86) B-lymphocyte activation antigen. :@0.104762:0.437176:0.900447:0.437176:0.900447:0.417976:0.104762:0.417976:0.005806:0.015885:0.015885:0.010281:0.010281:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.009152:0.005806:0.005866:0.009152:0.010281:0.009152:0.009152:0.010281:0.010281:0.010281:0.005806:0.010281:0.005806:0.005866:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.005866:0.010281:0.005806:0.010281:0.010281:0.008043:0.005866:0.005806:0.010281:0.005866:0.005806:0.010281:0.009152:0.005866:0.013647:0.010281:0.006914:0.010281:0.006914:0.013647:0.014756:0.010281:0.010281:0.006914:0.005866:0.013647:0.006914:0.005806:0.010281:0.015885:0.010281:0.010281:0.010281:0.009152:0.010281:0.005806:0.009152:0.005866:0.009152:0.009152:0.005806:0.005806:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.005866:0.009152:0.010281:0.005806:0.005806:0.010281:0.009152:0.010281:0.005040:0.005040
This  paper presents  Tislelizumab’s molecular docking and dynamics simulations  with the :@0.104762:0.454280:0.900424:0.454280:0.900424:0.435081:0.104762:0.435081:0.012519:0.010281:0.005806:0.008043:0.005040:0.005534:0.010281:0.009152:0.010281:0.009152:0.006914:0.010583:0.010281:0.006914:0.009152:0.008043:0.009152:0.010281:0.005806:0.008043:0.005040:0.005171:0.011807:0.005806:0.008043:0.005806:0.009152:0.005806:0.005806:0.009152:0.010281:0.015885:0.009152:0.010281:0.005802:0.008043:0.010583:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.010583:0.010281:0.010281:0.009152:0.010281:0.005806:0.010281:0.010281:0.010583:0.009152:0.010281:0.010281:0.010583:0.010281:0.010281:0.010281:0.009152:0.015885:0.005806:0.009152:0.008043:0.010583:0.008043:0.005806:0.015885:0.010281:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.005040:0.005534:0.014756:0.005806:0.005806:0.010281:0.010583:0.005806:0.010281:0.008948:0.005040
receptor B7-2(CD86) and its downstream signaling proteins CTLA-4 and IL-6. When docked :@0.104762:0.471385:0.900344:0.471385:0.900344:0.452185:0.104762:0.452185:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.006975:0.013647:0.010281:0.006914:0.010281:0.006914:0.013647:0.014756:0.010281:0.010281:0.006914:0.006975:0.009152:0.010281:0.010281:0.006975:0.005806:0.005806:0.008043:0.006975:0.010281:0.010281:0.014756:0.010281:0.008043:0.005806:0.006914:0.009152:0.009152:0.015885:0.006975:0.008043:0.005806:0.010281:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.006975:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.008043:0.006975:0.013647:0.012519:0.012519:0.014756:0.006914:0.010281:0.006975:0.009152:0.010281:0.010281:0.006975:0.006914:0.012519:0.006914:0.010281:0.005241:0.006610:0.019231:0.010281:0.009152:0.010281:0.006975:0.010281:0.010281:0.009152:0.010281:0.009152:0.010079:0.005040
to B cell stimulatory factor-2 soluble IL-6 receptor alpha (sIL6Ra/CD126), Tislelizumab had :@0.104762:0.488489:0.900416:0.488489:0.900416:0.469289:0.104762:0.469289:0.005806:0.010281:0.007499:0.013647:0.007499:0.009152:0.009152:0.005806:0.005806:0.007499:0.008043:0.005806:0.005806:0.015885:0.010281:0.005806:0.009152:0.005806:0.010281:0.006914:0.010281:0.007499:0.006914:0.009152:0.009152:0.005806:0.010281:0.006511:0.006914:0.010281:0.007499:0.008043:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.007499:0.006914:0.012519:0.006914:0.010281:0.007499:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.007499:0.009152:0.005806:0.010281:0.010281:0.009152:0.007499:0.006914:0.008043:0.006914:0.012519:0.010281:0.013647:0.009152:0.005806:0.013647:0.014756:0.010281:0.010281:0.010281:0.006914:0.005241:0.007132:0.011807:0.005806:0.008043:0.005806:0.009152:0.005806:0.005806:0.009152:0.010281:0.015885:0.009152:0.010281:0.007499:0.010281:0.009152:0.010079:0.005040
a strong binding affinity of 329 kcal/mol and provided an excellent quality model with an :@0.104762:0.505593:0.900263:0.505593:0.900263:0.486394:0.104762:0.486394:0.009152:0.008870:0.008043:0.005806:0.006914:0.010281:0.010281:0.010281:0.008870:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.008870:0.009152:0.006550:0.006914:0.005806:0.010281:0.005806:0.005806:0.010281:0.008870:0.010281:0.006914:0.008870:0.010281:0.010281:0.010281:0.008870:0.010281:0.009152:0.009152:0.005806:0.005806:0.015885:0.010281:0.005806:0.008870:0.009152:0.010281:0.010281:0.008870:0.010281:0.006914:0.010281:0.010281:0.005806:0.010281:0.009152:0.010281:0.008870:0.009152:0.010281:0.008870:0.009152:0.010281:0.009152:0.009152:0.005806:0.005806:0.009152:0.010281:0.005806:0.008870:0.010281:0.010281:0.009152:0.005806:0.005806:0.005806:0.010281:0.008870:0.015885:0.010281:0.010281:0.009152:0.005806:0.008870:0.014756:0.005806:0.005806:0.010281:0.008870:0.009152:0.010079:0.005040
LGscore of 4.54. The type I membrane protein B7-2(CD86), a member of the immunoglobulin :@0.104762:0.522698:0.900374:0.522698:0.900374:0.503498:0.104762:0.503498:0.012519:0.014756:0.008043:0.009152:0.010281:0.006914:0.009152:0.005917:0.010281:0.006914:0.005927:0.010281:0.005241:0.010281:0.010281:0.005241:0.005552:0.012519:0.010281:0.009152:0.005917:0.005806:0.010281:0.010281:0.009152:0.005917:0.006914:0.005917:0.015885:0.009152:0.015885:0.010281:0.006914:0.009152:0.010281:0.009152:0.005917:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.005917:0.013647:0.010281:0.006914:0.010281:0.006914:0.013647:0.014756:0.010281:0.010281:0.006914:0.005241:0.005917:0.009152:0.005917:0.015885:0.009152:0.015885:0.010281:0.009152:0.006914:0.005917:0.010281:0.006914:0.005917:0.005806:0.010281:0.009152:0.005927:0.005806:0.015885:0.015885:0.010281:0.010281:0.010281:0.010281:0.005806:0.010281:0.010281:0.010281:0.005806:0.005806:0.010079:0.005040
superfamily, responded to docking with an affinity of −332.35 kcal/mol and LGscore of 2.54. :@0.104762:0.539802:0.900348:0.539802:0.900348:0.520602:0.104762:0.520602:0.008043:0.010281:0.010281:0.009152:0.006914:0.006914:0.009152:0.015885:0.005806:0.005806:0.008973:0.005241:0.006759:0.006914:0.009152:0.008043:0.010281:0.010281:0.010281:0.010281:0.009152:0.010281:0.006761:0.005806:0.010281:0.006759:0.010281:0.010281:0.009152:0.010281:0.005806:0.010281:0.010281:0.006759:0.014756:0.005806:0.005806:0.010281:0.006759:0.009152:0.010281:0.006759:0.009152:0.006550:0.006914:0.005806:0.010281:0.005806:0.005806:0.010281:0.006761:0.010281:0.006914:0.006759:0.011571:0.010281:0.010281:0.010281:0.005241:0.010281:0.010281:0.006759:0.010281:0.009152:0.009152:0.005806:0.005806:0.015885:0.010281:0.005806:0.006759:0.009152:0.010281:0.010281:0.006759:0.012519:0.014756:0.008043:0.009152:0.010281:0.006914:0.009152:0.006759:0.010281:0.006914:0.006759:0.010281:0.005241:0.010281:0.010281:0.005040:0.005040
Docking to the immune checkpoint protein receptor cytotoxic T-lymphocyte-associated protein-4 :@0.104762:0.556906:0.900386:0.556906:0.900386:0.537707:0.104762:0.537707:0.014756:0.010281:0.009152:0.010281:0.005806:0.010281:0.010281:0.003991:0.005806:0.010281:0.003991:0.005806:0.010281:0.009152:0.003991:0.005806:0.015885:0.015885:0.010281:0.010281:0.009152:0.003991:0.009152:0.010281:0.009152:0.009152:0.010281:0.010281:0.010281:0.005806:0.010281:0.005806:0.003991:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.003991:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.003991:0.009152:0.010281:0.005806:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.003629:0.010664:0.006914:0.005806:0.010281:0.015885:0.010281:0.010281:0.010281:0.009152:0.010281:0.005806:0.009152:0.006914:0.009152:0.008043:0.008043:0.010281:0.009152:0.005806:0.009152:0.005806:0.009152:0.010281:0.003991:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.006914:0.010079:0.005040
(CTLA-4/CD152)  had  a  binding  affinity  of  −305.91  kcal/mol,  facilitating  immunological :@0.104762:0.574011:0.900390:0.574011:0.900390:0.554811:0.104762:0.554811:0.006914:0.013647:0.012519:0.012519:0.014756:0.006914:0.010281:0.005806:0.013647:0.014756:0.010281:0.010281:0.010281:0.006914:0.005040:0.006239:0.010281:0.009152:0.010281:0.005040:0.006239:0.009152:0.005040:0.006239:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.005040:0.006239:0.009152:0.006552:0.006914:0.005806:0.010281:0.005806:0.005806:0.010281:0.005040:0.006239:0.010281:0.006914:0.005040:0.006237:0.011571:0.010281:0.010281:0.010281:0.005241:0.010281:0.010281:0.005040:0.006239:0.010281:0.009152:0.009152:0.005806:0.005806:0.015885:0.010281:0.005806:0.005241:0.005040:0.006239:0.006914:0.009152:0.009152:0.005806:0.005806:0.005806:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.005040:0.006237:0.005806:0.015885:0.015885:0.010281:0.010281:0.010281:0.005806:0.010281:0.010281:0.005806:0.009152:0.009152:0.005602:0.005040
control and cellular dissociation.  Tislelizumab and these target proteins exhibited persistent :@0.104762:0.591115:0.900378:0.591115:0.900378:0.571916:0.104762:0.571916:0.009152:0.010281:0.010281:0.005806:0.006914:0.010281:0.005806:0.008830:0.009152:0.010281:0.010281:0.008830:0.009152:0.009152:0.005806:0.005806:0.010281:0.005806:0.009152:0.006914:0.008830:0.010281:0.005806:0.008043:0.008043:0.010281:0.009152:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.005241:0.005040:0.003429:0.011805:0.005806:0.008043:0.005806:0.009152:0.005806:0.005806:0.009152:0.010281:0.015885:0.009152:0.010281:0.008830:0.009152:0.010281:0.010281:0.008830:0.005806:0.010281:0.009152:0.008043:0.009152:0.008830:0.005806:0.009152:0.006552:0.010281:0.009152:0.005806:0.008830:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.008043:0.008830:0.009152:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.009152:0.010281:0.008830:0.010281:0.009152:0.006914:0.008043:0.005806:0.008043:0.005806:0.009152:0.010281:0.005602:0.005040
and advantageous interactions in molecular dynamics studies. The STRING functional protein-:@0.104762:0.608220:0.895381:0.608220:0.895381:0.589020:0.104762:0.589020:0.009152:0.010281:0.010281:0.005765:0.009152:0.010281:0.010281:0.009152:0.010281:0.005806:0.009152:0.010281:0.009152:0.010281:0.010281:0.008043:0.005765:0.005806:0.010281:0.005806:0.009152:0.006914:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.005765:0.005806:0.010281:0.005765:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.005765:0.010281:0.010281:0.010281:0.009152:0.015885:0.005806:0.009152:0.008043:0.005765:0.008043:0.005806:0.010281:0.010281:0.005806:0.009152:0.008043:0.005241:0.005396:0.012519:0.010281:0.009152:0.005765:0.011410:0.012519:0.013647:0.006914:0.014756:0.014756:0.005765:0.006914:0.010281:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.009152:0.005806:0.005765:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.006713
protein network analysis supported our in silico docking and dynamic simulation results. This :@0.104762:0.625324:0.900422:0.625324:0.900422:0.606124:0.104762:0.606124:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.006572:0.010281:0.009152:0.005806:0.014756:0.010281:0.006914:0.010281:0.006572:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.008043:0.006572:0.008043:0.010281:0.010281:0.010281:0.010281:0.006914:0.005806:0.009152:0.010281:0.006572:0.010281:0.010281:0.006914:0.006572:0.005806:0.010281:0.006572:0.008043:0.005806:0.005806:0.005806:0.009152:0.010281:0.006572:0.010281:0.010281:0.009152:0.010281:0.005806:0.010281:0.010281:0.006572:0.009152:0.010281:0.010281:0.006572:0.010281:0.010281:0.010281:0.009152:0.015885:0.005806:0.009152:0.006572:0.008043:0.005806:0.015885:0.010281:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.006572:0.006914:0.009152:0.008043:0.010281:0.005806:0.005806:0.008043:0.005241:0.006201:0.012519:0.010281:0.005806:0.007846:0.005040
analysis also included comparisons of the binding modes of mAbs to protein receptors involved :@0.104762:0.642428:0.900436:0.642428:0.900436:0.623229:0.104762:0.623229:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.008043:0.005241:0.009152:0.005806:0.008043:0.010281:0.005241:0.005806:0.010281:0.009152:0.005806:0.010281:0.010281:0.009152:0.010281:0.005241:0.009152:0.010281:0.015885:0.010281:0.009152:0.006914:0.005806:0.008043:0.010281:0.010281:0.008043:0.005241:0.010281:0.006914:0.005241:0.005806:0.010281:0.009152:0.005231:0.010281:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.005241:0.015885:0.010281:0.010281:0.009152:0.008043:0.005231:0.010281:0.006914:0.005231:0.015885:0.014756:0.010281:0.008043:0.005241:0.005806:0.010281:0.005241:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.005241:0.006914:0.009152:0.009152:0.009152:0.010281:0.005806:0.010281:0.006914:0.008043:0.005241:0.005806:0.010281:0.010281:0.010281:0.005806:0.010281:0.009152:0.010079:0.005040
in the cancer hallmark mechanism(s), demonstrating that IL-6, B7-2, and CTLA-4 act and are :@0.104762:0.659533:0.900303:0.659533:0.900303:0.640333:0.104762:0.640333:0.005806:0.010281:0.006531:0.005806:0.010281:0.009152:0.006531:0.009152:0.009152:0.010281:0.009152:0.009152:0.006914:0.006531:0.010281:0.009152:0.005806:0.005806:0.015885:0.009152:0.006914:0.010281:0.006531:0.015885:0.009152:0.009152:0.010281:0.009152:0.010281:0.005806:0.008043:0.015885:0.006914:0.008043:0.006914:0.005241:0.006531:0.010281:0.009152:0.015885:0.010281:0.010281:0.008043:0.005806:0.006914:0.009152:0.005806:0.005806:0.010281:0.010281:0.006531:0.005806:0.010281:0.009152:0.005806:0.006531:0.006914:0.012519:0.006914:0.010281:0.005241:0.006531:0.013647:0.010281:0.006914:0.010281:0.005241:0.006531:0.009152:0.010281:0.010281:0.006531:0.013647:0.012519:0.012519:0.014756:0.006914:0.010281:0.006531:0.009152:0.009152:0.005806:0.006531:0.009152:0.010281:0.010281:0.006531:0.009152:0.006914:0.008948:0.005040
inhibited in group-mode. Functional enrichment analysis and molecular modelling supported :@0.104762:0.676637:0.900305:0.676637:0.900305:0.657437:0.104762:0.657437:0.005806:0.010281:0.010281:0.005806:0.010281:0.005806:0.005806:0.009152:0.010281:0.007862:0.005806:0.010281:0.007862:0.010281:0.006914:0.010281:0.010281:0.010281:0.006914:0.015885:0.010281:0.010281:0.009152:0.005241:0.007862:0.011410:0.010281:0.010281:0.009152:0.005806:0.005806:0.010281:0.010281:0.009152:0.005806:0.007862:0.009152:0.010281:0.006914:0.005806:0.009152:0.010281:0.015885:0.009152:0.010281:0.005806:0.007862:0.009152:0.010281:0.009152:0.005806:0.010281:0.008043:0.005806:0.008043:0.007862:0.009152:0.010281:0.010281:0.007862:0.015885:0.010281:0.005806:0.009152:0.009152:0.010281:0.005806:0.009152:0.006914:0.007862:0.015885:0.010281:0.010281:0.009152:0.005806:0.005806:0.005806:0.010281:0.010281:0.007862:0.008043:0.010281:0.010281:0.010281:0.010281:0.006914:0.005806:0.009152:0.010079:0.005040
the relationship between the hallmarks of the tumor microenvironment that link inflammation to :@0.104762:0.693741:0.900487:0.693741:0.900487:0.674542:0.104762:0.674542:0.005806:0.010281:0.009152:0.004899:0.006914:0.009152:0.005806:0.009152:0.005806:0.005806:0.010281:0.010281:0.008043:0.010281:0.005806:0.010281:0.004899:0.010281:0.009152:0.005806:0.014756:0.009152:0.009152:0.010281:0.004899:0.005806:0.010281:0.009152:0.004899:0.010281:0.009152:0.005806:0.005806:0.015885:0.009152:0.006914:0.010281:0.008043:0.004899:0.010281:0.006914:0.004899:0.005806:0.010281:0.009152:0.004899:0.005806:0.010281:0.015885:0.010281:0.006914:0.004899:0.015885:0.005806:0.009152:0.006914:0.010281:0.009152:0.010281:0.010281:0.005806:0.006914:0.010281:0.010281:0.015885:0.009152:0.010281:0.005806:0.004899:0.005806:0.010281:0.009152:0.005806:0.004899:0.005806:0.005806:0.010281:0.010281:0.004899:0.005806:0.010281:0.006914:0.005806:0.009152:0.015885:0.015885:0.009152:0.005806:0.005806:0.010281:0.010281:0.004899:0.005806:0.010079:0.005040
immunity. Tislelizumab may therefore be able to prevent these three proteins from acting. These :@0.104762:0.710846:0.900330:0.710846:0.900330:0.691646:0.104762:0.691646:0.005806:0.015885:0.015885:0.010281:0.010281:0.005806:0.005806:0.008973:0.005241:0.004540:0.011807:0.005806:0.008043:0.005806:0.009152:0.005806:0.005806:0.009152:0.010281:0.015885:0.009152:0.010281:0.004899:0.015885:0.009152:0.010281:0.004899:0.005806:0.010281:0.009152:0.006914:0.009152:0.006914:0.010281:0.006914:0.009152:0.004899:0.010281:0.009152:0.004899:0.009152:0.010281:0.005806:0.009152:0.004899:0.005806:0.010281:0.004899:0.010281:0.006914:0.009152:0.010281:0.009152:0.010281:0.005806:0.004899:0.005806:0.010281:0.009152:0.008043:0.009152:0.004899:0.005806:0.010281:0.006914:0.009152:0.009152:0.004899:0.010281:0.006914:0.010281:0.005806:0.009152:0.005806:0.010281:0.008043:0.004899:0.006914:0.006914:0.010281:0.015885:0.004899:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.005241:0.004542:0.012519:0.010281:0.009152:0.008043:0.008948:0.005040
findings may also shine light on Dostarlimab’s mode of action, which in 2022 achieved ground-:@0.104762:0.727950:0.895423:0.727950:0.895423:0.708751:0.104762:0.708751:0.006914:0.005806:0.010281:0.010281:0.005806:0.010281:0.010281:0.008043:0.005161:0.015885:0.009152:0.010281:0.005161:0.009152:0.005806:0.008043:0.010281:0.005161:0.008043:0.010281:0.005806:0.010281:0.009152:0.005161:0.005806:0.005806:0.010281:0.010281:0.005806:0.005161:0.010281:0.010281:0.005161:0.014756:0.010281:0.008043:0.005806:0.009152:0.006914:0.005806:0.005806:0.015885:0.009152:0.010281:0.005802:0.008043:0.005161:0.015885:0.010281:0.010281:0.009152:0.005161:0.010281:0.006914:0.005161:0.009152:0.009152:0.005806:0.005806:0.010281:0.010281:0.005241:0.005161:0.014756:0.010281:0.005806:0.009152:0.010281:0.005161:0.005806:0.010281:0.005161:0.010281:0.010281:0.010281:0.010281:0.005161:0.009152:0.009152:0.010281:0.005806:0.009152:0.010281:0.009152:0.010281:0.005161:0.010281:0.006914:0.010281:0.010281:0.010281:0.010281:0.006713
breaking success in a clinical study for colorectal cancer.:@0.104762:0.745055:0.586067:0.745055:0.586067:0.725855:0.104762:0.725855:0.010281:0.006914:0.009152:0.009152:0.010281:0.005806:0.010281:0.010281:0.006632:0.008043:0.010281:0.009152:0.009152:0.009152:0.008043:0.008043:0.006632:0.005806:0.010281:0.006632:0.009152:0.006632:0.009152:0.005806:0.005806:0.010281:0.005806:0.009152:0.009152:0.005806:0.006632:0.008043:0.005806:0.010281:0.010281:0.010281:0.006632:0.006914:0.010281:0.006914:0.006632:0.009152:0.010281:0.005806:0.010281:0.006914:0.009152:0.009152:0.005806:0.009152:0.005806:0.006632:0.009152:0.009152:0.010281:0.009152:0.009152:0.005802:0.005040
Vol. 2 - Issue 1:@0.743337:0.965677:0.857137:0.965677:0.857137:0.947594:0.743337:0.947594:0.011649:0.009239:0.005137:0.004620:0.004620:0.009239:0.004620:0.006153:0.004620:0.007188:0.007188:0.007188:0.010274:0.008205:0.004620:0.009239
103:@0.864761:0.971012:0.911903:0.971012:0.911903:0.940075:0.864761:0.940075:0.015300:0.015300:0.016540
Reference::@0.104762:0.814347:0.210548:0.814347:0.210548:0.792081:0.104762:0.792081:0.015687:0.010442:0.007832:0.010442:0.009149:0.010442:0.013076:0.010442:0.010442:0.007832
https://doi.org/10.1016/:@0.104762:0.833876:0.263127:0.833876:0.263127:0.817876:0.104762:0.817876:0.008399:0.004670:0.004670:0.008399:0.006535:0.004670:0.004670:0.004670:0.008399:0.008399:0.004670:0.004200:0.008399:0.005277:0.008399:0.004670:0.008399:0.008399:0.004200:0.008399:0.008399:0.008399:0.008399:0.004670
j.imu.2023.101323:@0.104762:0.854865:0.232165:0.854865:0.232165:0.838865:0.104762:0.838865:0.004670:0.004200:0.004670:0.013070:0.008399:0.004200:0.008399:0.008399:0.008399:0.008399:0.004200:0.008399:0.008399:0.008399:0.008399:0.008399:0.008399